Expanding Clinical Trial Diversity - Bristol Myers Squibb

Transforming clinical trials: The Bristol Myers Squibb Foundation expands diversity among clinical researchers

More diverse clinical researchers and investigators can act as a bridge to underrepresented patient populations, potentially increasing their participation in clinical trials. The Foundation has an ambitious program to train hundreds of community-oriented clinicians in the next five years.

In 2021, the Bristol Myers Squibb Foundation (BMSF), with its partners, National Medical Fellowships and the American Association for Cancer Research, began training the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program (BMSF DCTCDP).

The group of early-stage investigators consists of 34 women and 18 men, 70 percent of whom meet the definition of underrepresented in medicine. They are the first of 250 community-oriented clinical trialists who will be trained by 2027.

The BMSF DCTCDP was launched as one of the health equity and diversity and inclusion commitments made in 2020 by the Foundation and its donor, Bristol Myers Squibb. Participants are trained as world-class clinical research scientists with competencies in effective community outreach and engagement. This new generation of investigators will have the potential to transform the clinical research landscape by increasing the diversity of participants.

“Many aspects of the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program make it unique,” said Eliseo J. Pérez-Stable, M.D., Director of the National Institute on Minority Health and Health Disparities, National Institutes of Health. “Its focus on helping clinical trialists become experienced in community engagement research methods is key to developing the trust necessary to realize an increase in clinical trial participation by people of color, yet we have not seen this in any other program of this kind.”

More Community Stories


The power of inclusion >
Partnering with HBCUs >
Environmental, social & governance highlights >
Pursuing sustainable science >
Transforming patients' lives through science

The touch that transforms

2021 Annual Report


Visit bms.com to see how we're bringing a human touch to everything we do. 

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.